The Global Market for AIDS/HIV Testing and Treatment
May 10, 2011
Wellesley, Mass. – According to a new technical market research report, THE GLOBAL MARKET FOR AIDS/HIV TESTING AND TREATMENT (PHM058A) from BCC Research (www.bccresearch.com), the value of the global market for AIDS/HIV testing and treatment was an estimated $11.8 billion in 2011, but is expected to increase to more than $14.1 billion in 2016, for a 5-year compound annual growth rate (CAGR) of 4.6%.
The largest segment of the market, made up of branded products, is projected to increase at a CAGR of 4.6% to nearly $13.3 billion in 2016, after being valued at an estimated $11.1 billion in 2011.
The other segment, made up of generic and discounted products, is estimated at $690 million in 2011, but is expected to increase at a CAGR of 4.4% to reach $830 million in 2016.
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the management of HIV infection and AIDS.
HIV/AIDS is one of the most catastrophic threats to human health throughout the world. Advanced treatment options and improved methods of diagnosis have helped to moderate the growth of the epidemic and this has presented opportunities for companies prepared to engage actively in this field. However, the management of HIV/AIDS is still, in many respects, an unfulfilled market and there is an ongoing urgent need for promising new research directions as well as optimal exploitation of the treatment and diagnostic options already developed.
This report discusses the emergence of a considerable generic medicine component in the marketplace, alongside the presence of original branded medicines; profiles of both originator companies and generic suppliers are included and the role of governmental and charitable agencies explained.
This report is designed to satisfy the information needs of a wide variety of individuals involved in the pharmaceutical marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive, and up-to-date background on the marketplace in which they are operating.
The Global Market for AIDS/HIV Testing and Treatment( PHM058A )
Publish Date: Mar 2011
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Pharmaceuticals
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum
- Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
- AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR Forecast
Reports from Pharmaceuticals
Recent News
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand